Adult type 2 diabetics are at very high risk of obesity-associated hypertension, where the end result can be as grave as heart failure. The systems involved in the human body regarding these conditions can be complex, but scientists have identified cases of stroke and refractory hypertension that harbored increased plasma IgG, 5-hydroxytryptamine 2A receptor (5-HT2AR)-targeting autoantibodies.

Serotonin 2A-Receptor Decoy Peptide Lowers Blood Pressure

The goal was to test whether a decoy receptor peptide could lower blood pressure in an animal model of obesity-associated hypertension. The team developed the decoy receptor peptide, SCLLADDN (Sertuercept), and LifeTein synthesized it successfully for the project. Using Zucker hypertensive diabetic fatty rats as the model, the team proved their theory.

Results showed after implementing the decoy receptor peptide, acute and long-lasting significant systolic and diastolic blood pressure-lowering occurred within the rat models. This followed through without any long-term side effects after chronic administration. Hopefully, these results are fruitful in later applications and the same peptide can be used to help significantly lower blood pressure in humans afflicted with type 2 diabetes as well.


Zimering MB. A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinology, Diabetes and Metabolism Journal. 2021 Aug;5(2). DOI: 10.31038/edmj.2021523. PMID: 35035793; PMCID: PMC8759716.

A linear synthetic peptide, SCLLADDN (SN..8 or P4) having a sequence
identical to that of a fragment of the second extracellular loop region of the human 5-
hydroxytryptamine 2A receptor was synthesized at Lifetein, Inc (Hillsborough, NJ) and
had > 95% purity. Substitutions of SCLLADDN containing a single alanine amino acid
replacement, e.g. SALLADDN, SCLLADAN were synthesized at Lifetein, Inc (Hillsborough,
NJ) and had purity of > 95%.

Grinberg, M.; Burton, J.; Pang, K.C.; Zimering, M.B. Neuroprotective Effects of a Serotonin Receptor Peptide Follow-ing Sham vs. Mild Traumatic Brain Injury in the Zucker Rat. Preprints 2023, 2023050004. https://doi.org/10.20944/preprints202305.0004.v1

Alzheimer’s disease as we know it today is a horrible and currently incurable neurodegenerative disorder characterized by neuronal loss, memory impairment, and cognitive decline. Ongoing research is always looking for ways to combat or slow down this disorder, and one such area of interest is the related formation of senile amyloid plaques mainly composed of amyloid β (Aβ) peptides, whose aggregation is thought to be responsible for Alzheimer’s disease pathology. Researchers are implementing gallium nitride nanoparticles as a means to inhibit the formation of the Aβ40 amyloid peptides.


Gallium nanoparticles inhibit amyloid β peptide formation

LifeTein supplied the scientists with the Aβ40 peptide necessary for this research, where they would synthesize their nanoparticle with gallium nitrate and observe its inhibition on the peptide in vitro. Gallium nitrate in particular is of interest due to its biocompatibility and aqueous stability, allowing the substance to be useful in numerous biological applications.

After observing their interactions together using the likes of ThT fluorescence, CR absorbance, turbidity, and SEM imaging, the group concluded that the nanoparticle did in fact inhibit the crucial oligomeric nucleus formation of the amyloid β peptide. The group believes a key factor in this is the polarization characteristic of the nanoparticle, where even more polarization could mean more interaction between the nanoparticle and the peptide, and thus less intermolecular interactions among the Aβ40 peptide monomers to form amyloids. Hopefully the future sees more studies on these gallium nitrate nanoparticles, and how further modifications could benefit the fight against Alzheimer’s through these critical Aβ40 peptides.

Torres, K. M., Delgado, A. S., Serrano, E. R., Falcón-Cruz, N. V., Meléndez, A., Ramos, I., Du, D., & Oyola, R. (2021). Gallium nanoparticles as novel inhibitors of Aβ40 aggregation. In Materials Advances (Vol. 2, Issue 16, pp. 5471–5478). Royal Society of Chemistry (RSC). https://doi.org/10.1039/d1ma00461a